Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Viatris investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, yo.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Viatris Inc. (VTRS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) investors concerning the Company's possible violations of federal securities laws. On February 28, 2022, before the market opened, Viatris revealed that it had decided to undertake a global reshaping of its business, announcing that it had entered into an agreement to sell it biosimilars business to Biocon Biologics Limited and was seeki.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Viatris Inc. (VTRS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2022, before the market opened, Viatris revealed that it had decided to undertake a global reshaping of its business, announcing that it had entered into an agreeme.

The Law Offices of Frank R. Cruz Announces Investigation of Viatris Inc. (VTRS) on Behalf of Investors

NEW YORK , May 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

BorgWarner

CF Industries Holdings

JD.com

Leidos Hld

Organon & Co

QUALCOMM

Investing is a tug-of-war between bullish and bearish sentiment. Near-term price swings provide long-term investors with great entry points to pick up unfairly beaten-down stocks.

7 Stocks That Are Long Overdue for a Relief Rally

Viatris pays a decent dividend and its line of business should be relatively safe. But it hasn't yet demonstrated its ability to maintain a stable top or bottom line.

It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?

Amgen

Bristol-Myers

Cigna

Centene

Gilead Sciences

Labcorp Holdings Inc

Pfizer

The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.

9 Cheap Healthcare Stocks to Consider

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2023. SO WHAT: If you purchased Viatris securities during the Class Period y.

VTRS EQUITY ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – VTRS

PITTSBURGH , May 17, 2023 /PRNewswire/ -- Viatris Inc.  (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA on Tuesday, June 13, 2023. Chief Executive Officer Scott A.

Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

Ares Capital

Verizon

Ares Capital just might be the best ultra-high-yield dividend stock on the market right now. Verizon's dividend is on firmer ground than its Q1 results indicate.

3 High-Yield Dividend Stocks You Probably Didn't Know Warren Buffett Owns

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Viatris business and prospects, resulting in its stock trading at inflated prices.

VTRS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead the Viatris Class Action Lawsuit

Supplied medicines to approximately 1 billion patients globally PITTSBURGH , May 16, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2022 Sustainability Report showcasing its commitment, impact and progress on building sustainable access to medicine as it continues to make a positive difference across key areas including Access and Global Health, Our People, the Environment and the Community. Viatris supplied medicines to approximately 1 billion patients globally in 2022 "At Viatris, access is fundamental to our mission of empowering people worldwide to live healthier at every stage of life," said Scott A.

Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP, a shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of Viatris Inc. ("Viatris") (NASDAQ: VTRS) investors who acquired securities between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”). If you are a shareholder who incurred losses during this period, you have until July 14, 2023, to move the court to become a lead plaintiff in this action. Join Class Action Here: https://www.johnsonfis.

Viatris Faces Shareholder Class Action Lawsuit: Johnson Fistel Encourages Investors to Seek Compensation for Alleged Wrongdoings – VRTS

NEW YORK , May 16, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Viatris Inc. ("Viatris" or the "Company") (NasdaqGS: VTRS) violated federal securities laws. CURRENT INVESTIGATION DETAILS: Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022.

VTRS NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Viatris Inc.

NEW YORK , May 15, 2023 /PRNewswire/ -- Attention Viatris Inc. ("Viatris" or the "Company") (NasdaqGS: VTRS) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Viatris and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022.

VTRS ALERT: The Law Offices of Vincent Wong Investigate Viatris Inc. for Potential Violations of Securities Laws

NEW YORK , May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Viatris Inc. (NasdaqGS: VTRS) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/viatris-inc-class-action-loss-submission-form/?from=4 Further details on the investigation: Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022. Additionally, Viatris announced that it was seeking to divest additional business assets and undertaking a significant global reshaping of its business, which would focus on developing products in three core therapeutic areas: ophthalmology, gastrointestinal and dermatology.

VTRS FRAUD ALERT: Jakubowitz Law is Investigating Viatris Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , May 11, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris" or the "Company") (NasdaqGS: VTRS) concerning possible violations of federal securities laws. Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022.

VTRS INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Viatris Inc.

NEW YORK , May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc.: Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022. Additionally, Viatris announced that it was seeking to divest additional business assets and undertaking a significant global reshaping of its business, which would focus on developing products in three core therapeutic areas: ophthalmology, gastrointestinal and dermatology.

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of an Investigation and Potential Class Action Lawsuit - (NasdaqGS: VTRS)

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris Inc. (NASDAQ:VTRS ) Q1 2023 Results Conference Call May 8, 2023 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Incoming Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Glenn Santangelo - Jefferies Chris Schott - JPMorgan Balaji Prasad - Barclays David Amsellem - Piper Sandler Ash Verma - UBS Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Group Operator Good morning. My name is Gretchen, and I will be your conference operator today.

Viatris Inc. (VTRS) Q1 2023 Earnings Call Transcript

Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.93 per share a year ago.

Viatris (VTRS) Tops Q1 Earnings Estimates

Alvotech SA

Fuji Pharma Co., Ltd. is mainly a generics pharma company focused on the less volatile Japanese generics market, whose market structure is associated with less regulatory risks, competition, and generics profitability risks. Its generics focus is a positive thing in Japan since regulators want a greater generics to share in healthcare expenditure, and its products for women are low-penetration and received recent government support.

Fuji Pharma: High Scope For Growth In U.S. Foray, Biosimilars, And Women's Health Drugs

Reports Total Revenues of $3.73 billion; U.S. GAAP Net Earnings of $225 million; Adjusted EBITDA of $1.34 billion; U.S. GAAP Net Cash Provided by Operating Activities of $971 million; and Free Cash Flow of $923 million for the Quarter Expects Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow to be at Midpoint of 2023 Guidance Ranges[1] Reaffirms 2024 Phase 2 Outlook from November 7 Strategic Update Returns Approximately $400 million of Capital to Shareholders in First Quarter Through Dividends and Share Repurchases Pays Down Debt of $546 million in First Quarter Board of Directors Declares Quarterly Dividend of $0.12 per Share PITTSBURGH , May 8, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024. Executive Commentary Viatris CEO Scott A.

Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

NEW YORK , April 28, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris" or the "Company") (NasdaqGS: VTRS) concerning possible violations of federal securities laws.   Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022.

VTRS INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Viatris Inc.

News for Viatris Stock (VTRS)